GovChime
Notice ID: 9681881e0054ce9ab1e0d99f52e3a4beAward NoticeAwarded

Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

Awarded on September 26, 2019. Full description on SAM.gov.

Awarded tounder 75N93019C00071 (source: SAM.gov award notice)• $57.3M

Overview

Posted
September 27, 2019
Notice type
Award Notice
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Health and Human Services

Notice details

PSC
A: RESEARCH AND DEVELOPMENT
Last updated
Dec 6, 2025
Award date
Sep 26, 2019
Award amount (SAM.gov award notice)
$57.3M

Identifiers

Solicitation number
BAA-NIAID-NIHAI201700104
Notice ID
9681881e0054ce9ab1e0d99f52e3a4be
Award number (PIID)
75N93019C00071

Description

Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Divisions of AIDS (DAIDS); Allergy, Immunology and Transplantation (DAIT); and Microbiology and Infectious Diseases (DMID) have a joint requirement for development of the Immune Mechanisms of Protection Against Mycobacterium tuberculosis center (IMPAc-TB) program to gain a comprehensive understanding of the nature, location and timing of protective immune responses required to prevent initial Mtb infection, development of stable latent infection, or transition to active TB disease. Description The goal of this program is to establish an integrated multi-disciplinary team of highly collaborative investigators that will plan and conduct iterative, in-depth immunologic analyses of tissue-specific and systemic responses in small animals, non-human primates (NHPs), and humans to identify the key immune responses needed for protection against Mtb; identify immunologic targets that can be used to improve TB vaccine strategies; determine the impact of HIV/SIV and Nontuberculous Mycobacteria (NTM) infection(s) on relevant immune responses to Mtb infection or TB vaccines; and identify how bacterial immune evasion mechanisms subvert immune responses to Mtb. The IMPAc-TB team will be expected to develop Standard Operating Procedures and assay harmonization methods to be implemented by the center's members; conduct in-depth immunologic analyses of tissue-specific and systemic responses against Mtb/TB in small animals, non-human primates (NHPs), and humans, including examination of host responses to BCG or novel, promising vaccine candidates (pre- and/or post-exposure candidates); collaborate with existing NIAID-supported and other TB programs; and distribute positive and negative study results, reagents and other resources within a center, between centers (if applicable), to other NIAID-supported programs, and the broader research community to facilitate the development of improved TB vaccines. To achieve the IMPAc-TB program goals, Contractors will be responsible for the following activities: • Leadership structure: providing a Leadership Team to oversee center activities and be responsible for the planning and conduct of the IMPAc-TB center's proposed studies • Data and resource management system used for the storage, retrieval and analysis of center-generated data; cataloging/reporting of all center-generated reagents and research resources; and sharing of positive and negative study results and research resources within the center, to other NIAID-supported programs, and the broader research community in a timely manner through existing NIAID-supported programs (e.g., ImmPort, the Bioinformatics Resource Centers (PATRIC), BEI Resources) or other public portals or repositories designated by NIAID. • Conduct in-depth immunologic analyses to provide novel insights into the immune responses required to (1) protect a host from initial Mtb infection, (2) establish a latent infection, and/or (3) progress to active TB disease. These in-depth immune analyses should include a systemic analysis (i.e., not limited to a single component) of the immune system. Each IMPAc-TB team must examine at least two (2) of these three (3) Mtb/TB stages and conduct iterative immunologic studies using small animal models, non-human primate (NHP) and human studies. The immunologic studies should seek to move beyond analysis of single arms of the immune system and progress toward understanding how complex immune networks and interacting components generate a given biological outcome. The use of relevant small animal models that go beyond commonly used laboratory mouse strains is strongly encouraged. In addition, investigation of multiple clinically-relevant Mtb strains in animal challenge studies is encouraged. It is anticipated that one to three (1-3) cost reimbursement, completion type contracts will be awarded with performance beginning on or about August 01, 2019. NIAID anticipates funding up to $19.5M for all awards (direct and indirect costs combined) resulting from this BAA. Due to the inherent unknowns in a BAA (offeror developed SOW), it is difficult to determine the exact period of performance. The Government anticipates an initial, non-severable, completion portion of work. Dependent upon offeror's technical approaches and proposed milestones, the Government may also negotiate additional non-severable, completion options. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about February 08, 2018, and may be accessed through FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. Where proposals will be received via the NIAID electronic Contract Proposal Submission (eCPS) website add the following: For this solicitation, NIAID requires proposals to be submitted electronically via the electronic Contract Proposal Submission (eCPS) website at https://ecps.niaid.nih.gov.

Full description on SAM.gov

Award Overview

Award Number

75N93019C00071

Award Amount (SAM.gov award notice)

$57.3M

Award Date

Sep 26, 2019

Awardee

Awardee UEI

UNVDZNFA8R29

Original Solicitation

Notice ID: 9681881e0054ce9ab1e0d99f52e3a4be

Posted Date: Sep 27, 2019

Original Response Deadline: Not specified

Contacts

Documents

No documents available.

Lifecycle

Solicitation:BAA-NIAID-NIHAI201700104
  1. Pre-Solicitation
  2. Solicitation
  3. Awarded

This opportunity has been awarded.

  1. 5×
    Pre-SolicitationJan 25, 2018

    Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

    Notice 300286084ee9c6477ec3dd5acd4d4dd2 on SAM.gov

  2. SolicitationAug 8, 2018

    Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

    Notice 1630482b34896f1e34c09f03f4fda92c on SAM.gov

  3. 3×
    AwardedCurrentSep 27, 2019

    Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

    Notice 9681881e0054ce9ab1e0d99f52e3a4be on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Amendment 0001 to this notice is to push out the anticipated posting of the solicitation to late November 2026. This is a pre-solicitation notice to synopsize the intention of the Defense Health Agency Contracting Activity (DHACA) to issue a Request for Proposal (RFP) for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle covering military medical research and development services. A historical pre-solicitation notice was posted under Notice ID# HT942626RE002, although there were various delays with getting a solicitation out in Fiscal Year 2026. This notice is taking over where Notice ID# HT942626RE002 left off. No further delays are anticipated at this time for this on-ramp. The eventual RFP will be set-aside for small businesses certified under the Small Business Administration 8(a) Program. The Government anticipates making multiple new awards under this on-ramp, and all new awards will align with the existing unrestricted contract vehicle. This notice is not a request for proposals and does not commit the Government to any contractual agreement. The OMNIBUS IV contract vehicle was awarded under full and open competition with a base ordering period of 20 June 2022 through 19 June 2027 and an Option Ordering Period of 20 June 2027 - 19 June 2032. Task orders may be competed under fair opportunity (providing all Contract Holders within a Market Segment the opportunity to submit a proposal) or an exception to fair opportunity (such as set-asides for small businesses or applicable small business socioeconomic categories). The cumulative ceiling of this unrestricted IDIQ contract vehicle is $10 billion. To date, the accumulated awarded task order value (including future unexercised option periods) is over $690 million across 61 task orders. Task Orders have been issued by a growing number of end users including DHACA, the U.S. Army Medical Research Acquisition Activity (now integrated into DHACA), the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. When excluding the task orders simply providing a minimum guarantee to the existing Contract Holders, 61 task orders have been issued off this contract vehicle with 8 task orders being set aside for the 8(a) Program and 15 task orders being awarded to an 8(a) Participant (based on the most recent representations at the contract level). 42 task orders have been awarded so far to small businesses under this contract vehicle. Of the 61 task orders, 95% were awarded during the Government Fiscal Years 2024 - 2026. Please see attachments for further details.
-Pre-SolicitationOpen
Please see attached Sources Sought. Questions & Answers attached.
-Market Research11/12/2026
UPDATE: The purpose of Amendment 1 to DARPA-PA-26-137, the Firefox Program Solicitation (PS), is to update the deadlines for OPP submissions and presentations. The Defense Advanced Research Projects Agency (DARPA) has developed a non-invasive coherent optical system capable of recording neural signals in humans. To expand this foundational technology and enable the development of revolutionary, non-invasive brain-computer interfaces (BCIs), DARPA's Firefox program is soliciting approaches to overcome key technological hurdles: 1) development of components enabling dynamic rastering/scanning of the incoming coherent optical signal to target multiple regions of interest and 2) development of new data processing architectures beyond the digital domain to handle the high data rates and computational burden inherent to scaling the amount of neural data recorded by the optical system. The ultimate goal of the Firefox program is to use these innovations to develop a 100-channel, non-invasive BCI with 50-micron spatial and 100-microsecond temporal resolution.
-Solicitation11/30/2026
The purpose of this Special Notice (SN) is to provide public notification of additional research areas of interest to the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO), specifically for the forthcoming Laguna program. When released, the solicitation will be made available at https://sam.gov/. Additionally, this SN may be amended with a draft solicitation when available.
-Special Notice11/30/2026
PLEASE SEE THE ATTACHED DOCUMENTS FOR DETAILS. QUOTES WILL NOT BE REVIEWED OR ACCEPTED. IF YOU FEEL YOUR COMPANY CAN PROVIDE THIS SERVICE, SUBMIT A CAPABILITY STATEMENT.
-Special Notice11/09/2026

Additional Details

Solicitation Number

BAA-NIAID-NIHAI201700104

Archive Date

Oct 11, 2019